DUBLIN – Sanifit Therapeutics SA has found a taker for its phase III calcification inhibitor for kidney dialysis patients, SNF-472, in the shape of Vifor Pharma AG, which is acquiring the Spanish company outright for €205 million (US$231 million) up front, up to €170 million in potential clinical development, regulatory and market access milestones, as well as undisclosed commercial milestones.
Spain's Sanifit Laboratoris SL, a company developing treatments for calcification disorders, has dosed the first patient in a phase III trial of its lead asset, SNF-472, for the treatment of the rare and sometimes deadly disease calciphylaxis, a calcium accumulation disorder.